Cancer Immunology and Immunotherapy, 1432-0851

Tidskrift

Fler filtreringsmöjligheter
  1. Artikel i vetenskaplig tidskrift
  2. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics

    Felberg, A., Urban, A., Borowska, A., Stasiłojć, G., Taszner, M., Hellmann, A., Anna Maria Blom & Okrój, M., 2019, I : Cancer Immunology, Immunotherapy. 68, 4, s. 587-598

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression

    Hebb, J. P. O., Mosley, A. R., Vences-Catalán, F., Rajasekaran, N., Rosén, A., Ellmark, P. & Felsher, D. W., 2018 jan, I : Cancer Immunology, Immunotherapy. 67, 1, s. 47-60

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

    Ellmark, P., Mangsbo, S. M., Furebring, C., Norlén, P. & Tötterman, T. H., 2017 jan, I : Cancer Immunology and Immunotherapy. 66, 1, s. 1-7 7 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  5. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

    Bergqvist, V., Erik Hertervig, Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Ana Carneiro & Marsal, J., 2017, I : Cancer Immunology and Immunotherapy. 66, 5, s. 581-592

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.

    Okroj, M., Emelie Holmquist, Nilsson, E., Anagnostaki, L., Karin Jirström & Anna Blom, 2015, I : Cancer Immunology and Immunotherapy. 64, 4, s. 467-478

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.

    Fritzell, S., Emma Sandén, Eberstål, S., Visse, E., Anna Darabi & Peter Siesjö, 2013, I : Cancer Immunology and Immunotherapy. 62, 9, s. 1463-1474

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

    Thoren, F. B., Anderson, H. & Strannegard, O., 2013, I : Cancer Immunology and Immunotherapy. 62, 10, s. 1547-1551

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  9. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.

    Eberstål, S., Badn, W., Fritzell, S., Esbjörnsson, M., Anna Darabi, Visse, E. & Peter Siesjö, 2012, I : Cancer immunology, immunotherapy : CII. 61, 8, s. 1191-1199

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. Changes in immunocompetent cells after interstitial laser thermotherapy of breast cancer.

    Huld-Haraldsdottir, K., Ivarsson, K., Jansner, K., Stenram, U. & Karl-Göran Tranberg, 2011, I : Cancer immunology, immunotherapy : CII. 60, s. 847-856

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

    van der Most, R. G., Currie, A. J., Mahendran, S., Prosser, A., Anna Darabi, Robinson, B. W. S., Nowak, A. K. & Lake, R. A., 2009, I : Cancer Immunology and Immunotherapy. 58, 8, s. 1219-1228

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  12. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

    Okroj, M., Corrales, L., Stokowska, A., Pio, R. & Anna Blom, 2009, I : Cancer immunology, immunotherapy : CII. 58, s. 1773-1782

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment. 1996 Submitted

    Belfrage, H., Dohlsten, M., Hedlund, G. & Kalland, T., 1997, I : Cancer Immunology and Immunotherapy. 44, 2, s. 77-82

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  14. Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo

    Belfrage, H., Dohlsten, M., Hedlund, G. & Kalland, T., 1995, I : Cancer Immunology and Immunotherapy. 41, 2, s. 87-94

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  15. Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity

    Belfrage, H., Bhiladvala, P., Hedlund, G., Dohlsten, M. & Kalland, T., 1994, I : Cancer Immunology and Immunotherapy. 38, 4, s. 265-71

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift